食管鳞癌中STMN3高表达及其促癌作用机制

doi:10.3969/j.issn.1004-616x.2025.02.001

Abstract

Abstract: OBJECTIVE：To investigate expression and mechanism of STMN3 in malignancy of esophageal squamous cell carcinoma (ESCC). METHODS：Expression of STMN3 in different tumors was analyzed in the TCGA database and its correlation with clinicopathological parameters was evaluated. CCLE database and Western blot were used to detect expression of STMN3 mRNA and protein levels in ESCC cell lines in vitro. Knockdown efficiency of STMN3 siRNA transfection in the cell lines was detected by RT-qPCR and Western blot，respectively. Effects of STMN3 on malignant phenotype of ESCC cells were detected by cell proliferation，colony formation，and cell apoptosis assays. The changes in the expression of proliferation-related proteins regulated by STMN3 were detected by Western blot. RESULTS：Compared with control group，STMN3 mRNA and protein were highly expressed in ESCC tissues and cell lines. STMN3 expression was associated with prognosis of patients，and those with high STMN3 expression had significantly worse prognosis (P<0.05). Knocking down STMN3 significantly inhibited the proliferation and colony formation of ESCC cells (P<0.01). In addition，the protein levels of EGFR and the phosphorylation levels of EGFR，S6，and SRC were significantly reduced. CONCLUSION：STMN3 was highly expressed in ESCC tissues，and STMN3 promoted the proliferation of ESCC cells by activating the EGFR-related signaling pathway.

Key words: STMN3, esophageal squamous cell carcinoma, cell proliferation, cell apoptosis, EGFR

CLC Number:

R735.1

GUO Jing, XIE Guanchao, WANG Yinong, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. High expression of STMN3 and its oncogenic mechanism in esophageal squamous cell carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(2): 89-95,104.

References

[1] HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[2] LIANG T T, LU L, SONG X T, et al. Combination of microtubule targeting agents with other antineoplastics for cancer treatment[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5):188777.
[3] ČERMÁK V, DOSTÁL V, JELÍNEK M, et al. Microtubule-targeting agents and their impact on cancer treatment[J]. Eur J Cell Biol, 2020, 99(4):151075.
[4] BELLETTI B, BALDASSARRE G. Stathmin:a protein with many tasks. New biomarker and potential target in cancer[J]. Expert Opin Ther Targets, 2011, 15(11):1249-1266.
[5] RONG B X, CAI X G, LIU H, et al. Stathmin-dependent molecular targeting therapy for malignant tumor:the latest 5 years' discoveries and developments[J]. J Transl Med, 2016, 14(1):279.
[6] JU W T, MA H L, ZHAO T C, et al. Stathmin guides personalized therapy in oral squamous cell carcinoma[J]. Cancer Sci, 2020, 111(4):1303-1313.
[7] ZARIN B, ESHRAGHI A, ZARIFI F, et al. A review on the role of tau and stathmin in gastric cancer metastasis[J]. Eur J Pharmacol, 2021, 908:174312.
[8] XIE Z, ZHEN T T, LIN Y, et al. The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy[J]. Gland Surg, 2022, 11(11):1808-1816.
[9] ZHONG F J, SUN B, CAO M M, et al. STMN2 mediates nuclear translocation of Smad2/3 and enhances TGFβ signaling by destabilizing microtubules to promote epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Cancer Lett, 2021, 506:128-141.
[10] ZHANG Y M, NI S L, HUANG B, et al. Overexpression of SCLIP promotes growth and motility in glioblastoma cells[J]. Cancer Biol Ther, 2015, 16(1):97-105.
[11] SINGER S, MALZ M, HERPEL E, et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer[J]. Cancer Res, 2009, 69(6):2234-2243.
[12] NAIR S, BORA-SINGHAL N, PERUMAL D, et al. Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner[J]. Mol Cancer, 2014, 13:173.
[13] XIE X M, BARTHOLOMEUSZ C, AHMED A A, et al. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP[J]. Mol Cancer Ther, 2013, 12(6):1099-1111.
[14] LAWRENCE E J, CHATTERJEE S, ZANIC M. More is different:Reconstituting complexity in microtubule regulation[J]. J Biol Chem, 2023, 299(12):105398.
[15] PAIM L M G, LOPEZ-JAUREGUI A A, MCALEAR T S, et al. The spindle protein CKAP2 regulates microtubule dynamics and ensures faithful chromosome segregation[J]. Proc Natl Acad Sci USA, 2024, 121(9):e2318782121.
[16] LU Y, LIU C, XU Y F, et al. Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition[J]. Hepatobiliary Pancreat Dis Int, 2014, 13(4):386-394.
[17] CAMPANACCI V, GIGANT B. The C-terminus of stathmin-like proteins governs the stability of their complexes with tubulin[J]. Biochem Biophys Res Commun, 2023, 682:244-249.
[18] LIPS E H, VAN EIJK R, DE GRAAF E J R, et al. Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis[J]. BMC Cancer, 2008, 8:314.
[19] KWAK Y, NAM S K, PARK Y, et al. Distinctive phenotypic and microenvironmental characteristics of neuroendocrine carcinoma and adenocarcinoma components in gastric mixed adenoneuroendocrine carcinoma[J]. Mod Pathol, 2024, 37(10):100568.
[20] SHEN C, YAN Y, YANG S B, et al. Construction and validation of a bladder cancer risk model based on autophagy-related genes[J]. Funct Integr Genomics, 2023, 23(1):46.
[21] WU X P, SOOMAN L, LENNARTSSON J, et al. Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells[J]. Int J Oncol, 2013, 42(1):297-304.
[22] ZARYOUH H, DE PAUW I, BAYSAL H, et al. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma[J]. Med Res Rev, 2022, 42(1):112-155.
[23] YANG Y M, HONG P, XU W W, et al. Advances in targeted therapy for esophageal cancer[J]. Signal Transduct Target Ther, 2020, 5(1):229.
[24] WANG Y N, LIU C, CHEN H, et al. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma[J]. Signal Transduct Target Ther, 2024, 9(1):153.
[25] YI Y W, YOU K S, PARK J S, et al. Ribosomal protein S6:a potential therapeutic target against cancer-[J]. Int J Mol Sci, 2021, 23(1):48.
[26] ARTEMENKO M, ZHONG S S W, TO S K Y, et al. p70 S6 kinase as a therapeutic target in cancers:More than just an mTOR effector[J]. Cancer Lett, 2022, 535:215593.
[27] PANWAR V, SINGH A, BHATT M, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease[J]. Signal Transduct Target Ther, 2023, 8(1):375.
[28] PELAZ S G, TABERNERO A. Src:coordinating metabolism in cancer[J]. Oncogene, 2022, 41(45):4917-4928.
[29] POH A R, ERNST M. Functional roles of SRC signaling in pancreatic cancer:Recent insights provide novel therapeutic opportunities[J]. Oncogene, 2023, 42(22):1786-1801.
[30] CHEN Z W, OH D, DUBEY A K, et al. EGFR family and Src family kinase interactions:mechanics matters-[J]. Curr Opin Cell Biol, 2018, 51:97-102.
[31] ÁLVAREZ-VÁZQUEZ A, SAN-SEGUNDO L, CERVERÓ-GARCÍA P, et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models[J]. Neuro Oncol, 2024, 26(7):1230-1246.

High expression of STMN3 and its oncogenic mechanism in esophageal squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HUANG Ji, LI Zixuan, XU Jiaqi, LUO Xiu, SUN Zhenxiao. Effect of glycyrrhizic acid on human lung adenocarcinoma cells and its mechanism [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 56-62.
[2]	CHEN Jiao, LIU Qing, HUANG Conggai, ZHENG Shutao, LIU Tao, LU Xiaomei. miR-let-7a-5p targeted regulation of SNAP23 and malignant progression of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 63-71.
[3]	HUANG Xiaoyan, WU Fangcai, LIU Cantong, HUANG Jiatao, XU Yiwei. Detection of both serum MMP1 and P53 autoantibody for the diagnosis of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 305-308,324.
[4]	XIAO Xue, LU Xiaotong, CHEN Siqi, JIANG Yujuan, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Inhibitory effect and underlying mechanism of KW-2478 on proliferation of colorectal cancer cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 202-207.
[5]	SUN Xin, LI Shuang, LU Xue, CAI Tianjing, LIU Ya, LIU Qingjie, ZHANG Wei. Effect of low-dose ionizing radiation on oxidative stress and DNA damage repair in human lymphocytoid cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 94-99.
[6]	LIU Ruixue, LI Desheng, ZHANG Liwei. Characteristics of serum lipidomics among Kazakhs with esophageal squamous cell carcinomas based on the UPLC-MS/MS method [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 21-28,34.
[7]	HUANG Conggai, LIU Qing, ZHENG Shutao, LIU Tao, TAN Yiyi, PENG Tianyuan, CHEN Jiao, LU Xiaomei. Expression of CXCR2 in esophageal cancer tissues and its impact on biological behavior of esophageal cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 53-57,65.
[8]	ZHENG Yaqi, ZHAO Ziting, PAN Deyuan, LIU Luxin, XU Xiue, LIAO Liandi, WANG Shaohong, LI Enmin, XU Liyan. The expression of tonsoku-like DNA repair protein in esophageal carcinoma and its effect on the proliferation of esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 412-419.
[9]	WANG Yinong, LIU Guozheng, XIE Guanchao, FENG Dan, LI Sai, CAI Yan, ZHANG Yu, WANG Mingrong, HAO Jiajie. Inhibitory effects of ANXA2 knockdown on malignant phenotype of esophageal squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 445-451.
[10]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[11]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[12]	SHI Jianhong, CHEN Dingxiong, LU Xiaotong, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Inhibitory effect of ICG-001 on proliferation of esophageal squamous carcinoma cells and its molecular mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 187-191,196.
[13]	FENG Dan, FAN Zhilu, WANG Yinong, LI Sai, GUO Jing, CAI Yan, ZHANG Yu, WEI Wenqiang, WANG Mingrong, HAO Jiajie. P4HA2 promotes proliferation of esophageal squamous carcinoma cells via activating the EGFR/AKT/S6 signaling pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 87-94,101.
[14]	DENG Huiyan, LIU Chang, JIA Ying, LI Fang, YIN Danjing, TAN Zirui, SU Bing, LIU Yueping. Comparative detection of the EGFR gene in lung adenocarcinoma tissues and blood samples [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 21-25.
[15]	LI Ziyao, ZHANG Haiping, MADINIYET·Niyaz, JULATI·Ainiwaer, ZHANG Liwei, EDRIS·Awut. Clinicopathological significance of cystatin 6 protein expression in Kazakh esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 429-433,438.